Suven Life Sciences secures product patents in Australia, Hong Kong
Suven Life Science has secured one product patent from Australia and one product patent from Hong Kong corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2033 respectively. The granted claims of the patents include the class of selective M1 PAM and … Read more